在治疗高营养性心血管病方面,新药Aficamten 显示的结果优于Metopolol。 New drug aficamten shows better results than metoprolol in treating hypertrophic cardiomyopathy.

Aficamten,一种用于治疗高营养性心血管病的新药物,在最近的一项研究中显示,与标准治疗(motopolololol)相比,锻炼能力有了显著提高。 Aficamten, a new drug for hypertrophic cardiomyopathy (HCM), showed significant improvements in exercise capacity over the standard treatment, metoprolol, in a recent study. 称为MAPLE-HCM的第三阶段试验发现,Aficamten将最高氧气摄入量增加了1.1毫升/千克/分钟,而Metopololol则减少了1.2毫升/千克/分钟。 The Phase 3 trial, called MAPLE-HCM, found that aficamten increased peak oxygen uptake by 1.1 mL/kg/min, while metoprolol decreased it by 1.2 mL/kg/min. 结果表明aficamten可能是HCM更有效的治疗方法,该药物目前正在FDA审查中,预计将于2025年12月26日作出决定. The results suggest aficamten could be a more effective treatment for HCM, and the drug is currently under review by the FDA with a decision expected by December 26, 2025.